To appraise the clinical and cost effectiveness of nivolumab with ipilimumab within its marketing authorisation for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency.
Following on from an update from the company, NICE has decided to suspend this appraisal from its current work programme.
 
Status Suspended
Process STA pre-2018
ID number 1332

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 March 2018 Suspended, Following on from an update from the company, NICE has decided to suspend this appraisal from its current work programme.
20 November 2017 - 18 December 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
20 November 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance